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ABSTRACT The number of infections caused by Gram-negative pathogens carrying
carbapenemases is increasing, and the group of carbapenem-hydrolyzing class D
-lactamases (CHDLs) is especially problematic. Several clinically important CHDLs
have been identified in Acinetobacter baumannii, including OXA-23, OXA-24/40, OXA-
58, OXA-143, OXA-235, and the chromosomally encoded OXA-51. The selection and
dissemination of carbapenem-resistant A. baumannii strains constitutes a serious
global threat. Carbapenems have been successfully utilized as last-resort antibi-
otics for the treatment of multidrug-resistant A. baumannii infections. However,
the spread of OXA carbapenemases is compromising the continued use of these
antimicrobials. In response to this clinical issue, it is necessary and urgent to de-
sign and develop new specific inhibitors with efficacy against these enzymes.
The aim of this work was to characterize the inhibitory activity of LN-1-255 (a
6-alkylidene-2-substituted penicillin sulfone) and compare it to that of two estab-
lished inhibitors (avibactam and tazobactam) against the most relevant enzymes of
each group of class D carbapenemases in A. baumannii. The -lactamase inhibitor
LN-1-255 demonstrated excellent microbiological synergy and inhibition kinetics pa-
rameters against all tested CHDLs and a significantly higher activity than tazobactam
and avibactam. A combination of carbapenems and LN-1-255 was effective against
A. baumannii class D carbapenemases. Docking assays confirmed the affinity of LN-1-
255 for the active site of these enzymes. LN-1-255 represents a potential new
-lactamase inhibitor that may have a significant role in eradicating infections
caused by A. baumannii isolates carrying CHDLs.
KEYWORDS -lactamase inhibitors, Acinetobacter baumannii, antimicrobial
resistance, carbapenem-hydrolyzing class D -lactamases
The Gram-negative Acinetobacter baumannii may be the pathogen that has evolvedthe most drug resistance in recent decades. While A. baumannii was an uncommon
infectious agent in the 1970s and 1980s, presently this human pathogen is associated
with a broad spectrum of infectious diseases, including pneumonia and bloodstream
infections (1, 2). Most clinical strains of A. baumannii are multidrug resistant (3, 4), which
dramatically reduces the available treatment options.
In the available clinical arsenal of antimicrobials, the -lactams comprise more than
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60% of the world’s antibiotics (5, 6). The dissemination and expression of -lactamase
enzymes is the most relevant mechanism of resistance in Gram-negative bacteria,
including A. baumannii. -Lactamases confer resistance to -lactams via the cleavage of
the -lactam ring and the release of an inactive product, preventing the binding of
drugs to the target penicillin-binding proteins.
Four molecular classes of -lactamases are recognized based on their amino acid
sequences. Three of them, classes A, C, and D, are active-site serine enzymes, and the
other one, class B, contains zinc-dependent enzymes (7). Class D (also known as the
OXA-type -lactamases) is the fastest-growing class of -lactamases, with more than
500 reported enzymes (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA313047). The
OXA-like enzymes are divided into three categories based on their substrate specific-
ities: narrow-spectrum enzymes, such as OXA-1 or OXA-10, extended-spectrum
-lactamases (ESBLs), such as OXA-13 or OXA-17, and carbapenem-hydrolyzing class D
-lactamases (named CHDLs), such as OXA-23 or OXA-24/40 (8). From the first descrip-
tion of OXA-23 (9), the number of CHDLs discovered worldwide has dramatically
increased in problematic Gram-negative pathogens, such as Pseudomonas aeruginosa
or Enterobacteriaceae, and mostly in A. baumannii (10).
Until 1 decade ago, the most clinically relevant -lactamases were the ESBLs and the
AmpC -lactamases, which are unable to hydrolyze carbapenems. However, in recent
years there has been an increase in the number of -lactamase carbapenemases, of
which the group of CHLDs is especially problematic. Several CHDLs have been identi-
fied in A. baumannii, including the mostly acquired OXA-23, OXA-24/40, OXA-58,
OXA-143, and OXA-235 and the naturally occurring OXA-51 (11–16). These enzymes
were the first CHDLs described in each of the six families of CHDLs in A. baumannii and
constitute representative examples of the OXA-23-like, the OXA24/40-like, the OXA-58-
like, the OXA-143-like, the OXA-235-like, and the OXA-51-like enzymes (16–18). These
carbapenem-hydrolyzing class D -lactamases are the main enzymes responsible for
the majority of infections caused by carbapenem-resistant A. baumannii in clinics
around the world (19, 20), with OXA-23 being the major source of carbapenem
resistance in this pathogen (21). The OXA-51 enzyme is regarded as a weak carbap-
enemase; however, it can confer resistance to carbapenems when its gene acquires
a strong promoter by upstream insertion of an insertion sequence (IS) or becomes
located in a plasmid, resulting in increased expression rates. These OXA-51-related
enzymes are intrinsic to A. baumannii and are naturally found on its chromosome
(18, 22).
Clinical selection and dissemination of carbapenem-resistant A. baumannii strains
constitutes a serious threat associated with severe adverse clinical outcomes, including
increased mortality (23, 24). The prevalence and plasmid-mediated dissemination of
carbapenemase genes is an important clinical challenge. The carbapenems have been
successfully utilized as last-resort antibiotics for the treatment of multidrug-resistant
Acinetobacter infections; however, the spread of OXA carbapenemases in the last
decade is seriously compromising the use of these antimicrobials, which is a major
obstacle in the preservation of carbapenem efficacy against A. baumannii. In the United
States, the percentage of A. baumannii isolates resistant to imipenem has increased
from an average of 10% between 1999 and 2005 to 48% in 2008 (25). In response to this
clinical issue, two strategies may preserve the utility of -lactams: (i) the design of new
-lactam antibiotics, which are able to evade the inactivation conferred by
-lactamases, and (ii) the design of specific inhibitors against -lactamases (26).
In clinical therapy, -lactamase inhibitors are routinely successfully used in
combination with -lactam antibiotics (i.e., amoxicillin-clavulanic acid, piperacillin-
tazobactam, ampicillin-sulbactam, etc.). However, these inhibitors mainly have affinity
for class A -lactamases and are ineffective in infections caused by pathogens carrying
class D carbapenemases (27). Avibactam, a new inhibitor of class A and C -lactamases,
is able to inhibit some OXA enzymes, but it has not been effective in any CHDL-
producing A. baumannii strains tested so far (28). Thus, the development of efficient
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inhibitors of A. baumannii class D carbapenemases is urgently needed to preserve the
efficacy of carbapenem antimicrobials (29).
Buynak et al. (30, 31) designed a group of 6-alkylidene-2-substituted penicillin
sulfones that are able to inhibit -lactamases, and the compound LN-1-255 demon-
strated significant potency (Fig. 1). LN-1-255 is able to inhibit class A -lactamases, such
as SHV-1 and -2 (31), and class D non-carbapenem-hydrolyzing enzymes, such as
OXA-10, -14, and -17 (32), and even has proven activity against the CHDLs OXA-24/40.
In 2010, the hydrophobic bridge of OXA-24/40 (composed of Tyr-112 and Met-223) was
shown to be important in conferring inhibition by LN-1-255. However, this bridge is not
a universal feature of CHDLs; for example, OXA-48 does not possess it. Nevertheless, we
have observed that LN-1-255 also confers significant inhibition against this carbapen-
emase in Enterobacteriaceae (33).
The aim of this work was to study the activity of inhibition of this compound in the
major representative enzymes of all families of CHDLs described to date in A. bauman-
nii. We compared the already demonstrated activity of this inhibitor against OXA-24/40
with its activity against the other OXA carbapenemases in A. baumannii. Microbiolog-
ical, kinetic, and molecular docking studies were performed in order to demonstrate the
synergy of LN-1-255 with carbapenems, as well as its inhibition activity against all of the
CHDLs of A. baumannii.
RESULTS
Microbiological experiments. MIC assays revealed differences between clinical
isolates and the isogenic strains expressing each CHDL protein tested (Table 1). High
resistance levels to carbapenems were observed in the ATCC 17978 strain containing
-lactamases, from basal MICs of 0.5 mg/liter to 4 to 128 mg/liter, except for the
transformant carrying OXA-235, which had the lowest MIC (2 mg/liter). The highest
MICs of carbapenems observed both in clinical isolates and ATCC 17978 transformants
were in those carrying OXA-24/40 and OXA-143. The hyperexpression of OXA-51-like in
the ATCC 17978 strain increased the MICs of carbapenems 8-fold.
To determine the synergy of LN-1-255 with the CHDLs of A. baumannii, in vitro
susceptibility to imipenem–LN-1-255, meropenem–LN-1-255, and ampicillin–LN-1-255
were compared in combination with the -lactamase inhibitors tazobactam and avibac-
tam. The most significant inhibitory results were obtained when inhibitors were used at
a concentration of 16 mg/liter. Tazobactam did not significantly decrease the MIC of
carbapenems in any ATCC 17978 transformant expressing an OXA enzyme (0- to 1-fold).
Avibactam decreased the MIC of both carbapenems of OXA-143 by 8-fold, OXA-58
decreased the MIC of imipenem and meropenem by 8- and 4-fold, respectively, and
OXA-24/40 decreased the MIC of meropenem by 4-fold. In the other combinations
tested, avibactam did not decrease the MIC against carbapenems. In contrast, LN-1-255
at the same concentration significantly decreased the MICs of carbapenems, with
FIG 1 -Lactamase inhibitors used in this study.
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LN-1-255-cotreated transformants displaying the basal level of susceptibility to carbap-
enems (Table 1, Fig. 2). ATCC 17978 transformants expressing OXA-51-like and OXA-235
had low MICs of carbapenems. The MIC of OXA-51-like to both imipenem and mero-
penem was 4 mg/liter, while the MIC of OXA-235 was 2 mg/liter. Therefore, the MIC of
ampicillin was also tested to better observe the inhibition of the MICs. The MIC of
OXA-51-like against ampicillin was 8,192 mg/liter, which decreased to 4,096 mg/liter,
1,024 mg/liter, and 32 mg/liter in the presence of tazobactam, avibactam, and LN-1-255,
respectively. Similarly, the MIC of ampicillin in OXA-235 was 2,048 mg/liter, which
decreased to 512 mg/liter, 128 mg/liter, and 32 mg/liter in the presence of tazobactam,
avibactam, and LN-1-255, respectively. In these two weak carbapenemases, we ob-
served a significantly better inhibitory activity with LN-1-255 than with the other two
inhibitors. When inhibitors were used at 4 mg/liter, LN-1-255 also had better inhibitory
activity than avibactam and tazobactam; however, the decrease in MIC was less than
that observed at 16 mg/liter.
Similar results were obtained with the A. baumannii clinical isolates tested, and
although LN-1-255 was able to increase the efficacy of -lactams, the MICs were slightly
higher than those observed in the ATCC 17978 transformants, mainly in the clinical
isolate carrying OXA-24/40. It is likely that other minor resistance mechanisms are
present in these clinical isolates. Nevertheless, following the EUCAST criteria, in the
presence of LN-1-255 all clinical isolates and transformants were susceptible to both
FIG 2 Assessment of synergy between inhibitors. Pictures represent checkerboard assays using imipenem and
inhibitors with cultures of A. baumannii ATCC 17978 and clinical isolate Ab1 (both carrying OXA-23). Pink wells
indicate growth and blue wells indicate growth inhibition.
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carbapenems (2 mg/liter), except the clinical isolate carrying OXA-24/40 (intermedi-
ate susceptibility to imipenem and meropenem) and the clinical isolate carrying
OXA-143 (intermediate susceptibility to meropenem) (34). The remaining data are
shown in Table 1.
The antimicrobial activity of the three inhibitors was also tested, and tazobactam
was the only one with intrinsic antimicrobial activity (MICs of 32 mg/liter for ATCC
17978 carrying the empty vector pET-RA and 32 to 128 mg/liter for the ATCC 17978
transformants carrying the OXA enzymes). Conversely, LN-1-255 and avibactam did not
show any intrinsic antimicrobial activity, with MICs of 1,024 mg/liter.
Checkerboard assays were also used to determine the activity of LN-1-255 in both
OXA-23 strains tested, the ATCC 17978 transformant and the clinical isolate. The MIC of
imipenem alone in the ATCC 17978 transformant carrying OXA-23 was 16 mg/liter,
while the addition of LN-1-255 at 8 mg/liter reduced the MIC of imipenem to 0.5
mg/liter, thus totally inhibiting the carbapenemase; however, the MIC of imipenem
decreased to 8 mg/liter with avibactam, and no decrease in MIC was detected in the
presence of tazobactam. Similarly, in the clinical isolate carrying OXA-23, the MIC of
imipenem alone was 32 mg/liter, which decreased to 2, 8, and 8 mg/liter in the
presence of LN-1-255, avibactam, and tazobactam (8 mg/liter), respectively (Fig. 2
reflects a representative assay performed with OXA-23). The checkerboard assays
performed with the remaining A. baumannii clinical isolates and transformants included
in this study were also in agreement with the MIC assays (Table 1 and data not shown).
Kinetic parameters of CHDL enzymes. Class D carbapenemases were purified, and
their steady-state kinetic parameters were measured. All purified enzymes could hy-
drolyze nitrocefin at a high rate, which has been previously reported (16, 35–37) (Table
2). Nitrocefin hydrolysis rates were used as a reference ([S]  Km, where [S] is the
concentration of the substrate) to perform the inhibition kinetics assays, with nitrocefin
as a reporter substrate (Table 3).
All enzymes, except OXA-51-like enzyme, demonstrated a Ki for LN-1-255 in the
nanomolar range (54 to 289 nM). Avibactam and tazobactam were different, with a Ki
of 9 to 154 M and 11 to 172 M, respectively, approximately 3 logs higher than the
affinity of LN-1-255. The OXA-51-like enzyme had a low affinity for inhibitors, with a Ki
of 56 M, 500 M, and 3,000 M for LN-1-255, avibactam, and tazobactam,
respectively. The OXA enzymes with the greatest affinity for LN-1-255 were OXA-23 and
OXA-235, which had a Ki of 88 and 54 nM, respectively.
Similarly, the 50% inhibitory concentration (IC50) of LN-1-255 was in the nanomolar
range (8 to 40 nM) while it was in the micromolar range for avibactam (1 to 35 M) and
tazobactam (2 to 28 M) for all tested enzymes except the OXA-51-like enzyme. The
OXA-51-like enzyme had an IC50 of 1.7 M, 35 M, and 5,000 M for LN-1-255,
avibactam, and tazobactam, respectively. The best IC50s for LN-1-255 were the same as
those for OXA-23 (12 nM) and OXA-235 (8 nM).
Inactivation efficiencies (kinact/KI) were determined with the three compounds. While
kinact values were similar between LN-1255, tazobactam, and avibactam, large differ-
ences were observed in the affinity (KI) of the three inhibitors, with the affinity of
LN-1-255 being 65- to 6,045-fold higher than that of tazobactam and 14- to 1,126-fold
higher than that of avibactam. As a consequence, the inactivation efficiencies were also
TABLE 2 Nitrocefin hydrolysis kinetics of CHDLsb
CDHL kcat (s1) Km (M) kcat/Km (M1 s1) [S]a (M)
OXA-23 177  52 170  45 1.04 350
OXA-24/40 27.0  15.1 29.1  7.7 0.93 100
OXA-58 50.9  25.7 30.2  5.6 1.68 100
OXA-143 20.3  4.9 41.4  15.4 0.49 150
OXA-235 130  73 59.9  11.6 2.17 150
OXA-51 123  8 248  44 0.50 350
aConcentration of nitrocefin, which was used as a reporter substrate.
bData represent the means from three independent experiments.
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higher for LN-1-255 than for tazobactam (117- to 3,847-fold) and avibactam (8- to
614-fold). Similarly, apparent onset of acylation (k2/K) values were higher for LN-1-255
than for avibactam and tazobactam, being 73- to 927-fold and 150- to 3,194-fold
higher, respectively.
The turnover number is the time-dependent partitioning of the initial enzyme/
inhibitor complex between hydrolysis and enzyme inactivation and is represented by
the equation tn  kcat/kinact. In the case of LN-1-255, the tn was very similar for all CHDLs
tested, between 2 and 6, except for OXA-51-like enzyme, which showed a tn number of
520. The turnover numbers for avibactam and tazobactam were significantly higher,
with 17 to 202 for avibactam and 51 to 4,180 for tazobactam, and even higher for
OXA-51-like enzyme, 9,600 and 20,000, respectively (Fig. 3). The tn of OXA-24/40 is
remarkably high for tazobactam, 13- to 84-fold higher than that of the other CHDLs. This
result was in agreement with the MICs observed for OXA-24/40 in the presence of
tazobactam, which was inactivated at the lowest concentration out of all the carbapen-
emases tested.
Computational studies of activity of LN-1-255 against CHDLs enzymes. Reason-
ing that the differences in inhibitory activity observed between the -lactamase
inhibitors evaluated in this study against the CHDLs enzymes are due to the binding
mode of these ligands in the serine active site of the enzymes, molecular docking
studies were performed. These studies were carried out using the program GOLD
version 5.2 (http://www.ccdc.cam.ac.uk/solutions/csd-discovery/components/gold/)
and the enzyme geometries of OXA-23 (2.14 Å; PDB code 4JF4) (38) and OXA-58 (2.6
Å; PDB code 4Y0U) (39), which are covalently modified by meropenem and 6-
hydroxymethylpenicillanate, respectively. In addition, atomic structure determinations
of OXA-143 and OXA-235 are not available, so their corresponding homology models
were constructed by using the SWISS-MODEL homology modeling web server (40). The
TABLE 3 Inhibition kinetics of A. baumannii CHDLa
-Lactamase and
substrate IC50 (M) Ki app (M) k2/K (M1 s1) KI (M) kinact (s1) kinact/KI (M1 s1) tn
OXA-23
Avibactam 8.93  0.99 105.56  3.08 101.37  15.96 203.93  22.6 0.057  0.009 286.60  61.78 150
Tazobactam 2.13  0.80 11.39  2.49 193.53  39.10 19.73  4.71 0.023  0.004 1180  77.48 51
LN-1-255 0.012  0.008 0.088  0.006 (2.90  0.03)  104 0.30  0.08 0.041  0.005 (1.39  0.29)  105 2
OXA-24
Avibactam 22.32  2.79 154.25  19.93 22.12  5.53 113.93  35.93 0.018  0.007 159.92  40.63 202
Tazobactam 27.91  2.55 78.07  30.05 28.65  8.19 12.38  3.14 0.007  0.002 724.48  364.13 4,180
LN-1-255 0.015  0.004 0.289  0.054 (2.05  0.74)  104 0.24  0.05 0.022  0.002 (9.82  3.21)  104 6
OXA-51
Avibactam 34.9  17.7 500 2.77  1.20 430.94  122.43 0.004  0.0008 9.28  0.93 9,600
Tazobactam 5000 3000 NDb 5000 ND ND 20,000
LN-1-255 1.70  0.37 56.80  27.76 17.67  4.41 29.82  7.81 0.0022  0.0005 74.9  3.8 520
OXA-58
Avibactam 6.06  2.56 71.04  10.95 119.40  39.80 62.5  21.43 0.022  0.006 388.99  162.73 53
Tazobactam 22.62  3.77 171.61  15.22 16.00  4.00 88.75  25.53 0.018  0.005 206.47  51.12 314
LN-1-255 0.041  0.009 0.350  0.052 (8.76  1.44)  103 0.30  0.09 0.022  0.008 (7.52  2.1)  104 4
OXA-143
Avibactam 11.94  2.43 50.44  11.25 194.92  77.97 107.33  40.15 0.072  0.028 681.13  8.13 110
Tazobactam 5.90  1.86 21.36  0.68 181.93  81.15 20.69  10.14 0.017  0.006 955.37  385.40 237
LN-1-255 0.014  0.003 0.166  0.016 (3.98  0.47)  104 0.09  0.03 0.018  0.003 (1.21  0.83)  105 3
OXA-235
Avibactam 1.44  0.34 9.33  1.41 290.32  17.34 5.73  1.01 0.016  0.006 2,808.64  585.87 17
Tazobactam 4.88  1.32 60.23  10.28 7.77  1.92 266.22  50.05 0.050  0.017 197.45  83.02 306
LN-1-255 0.008  0.003 0.054  0.010 (1.76  0.80)  104 0.044  0.025 0.024  0.007 (7.58  5.17)  105 3
aData represent the means from three independent experiments.
bND, not determined, due to very low inhibition.
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FIG 3 Plots of turnover numbers (tn). Ratio of inhibitor concentration to enzyme concentration necessary to decrease
the enzyme activity by 90%.
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resulting OXA-143 and OXA-235 structures had 88% and 61% sequence identity with
the templates of OXA-24/40 (PDB code 3PAG) and OXA-51 (PDB code 4ZDX), respec-
tively.
Comparison of the available crystal structures of OXA-23 (2.14 Å; PDB code 4JF4)
(38), OXA-24/40 (2.14 Å; PDB code 3G4P) (35), OXA-51 (1.61 Å; PDB code 5KZH) (41), and
OXA-58 (1.8 Å; PDB code 5BOH) (42) enzymes and the constructed three-dimensional
structures of OXA-143 and OXA-235 reveals (i) similarities in their overall structure
and (ii) a highly conserved active site and cleft located between the two domains
that are involved in hydrolysis (Fig. 4). It has been proposed that the ability of these
enzymes to hydrolyze carbapenems is provided by a tunnel-like entrance to the
active site formed by the side chains of a tyrosine or phenylalanine and a methi-
onine, with the exception of OXA-51, in which the latter is replaced by tryptophan
(43). The presence of a Trp residue makes the active site of OXA-51 particularly small
and inaccessible (see Fig. S1 in the supplemental material), which might explain its
reduced carbapenemase activity. The Tyr/Phe and Met residues are crucial for the
architecture of the tunnel-like active site that permits the specific accommodation of
carbapenems. In general, this tunnel-like structure of CHDL enzymes forms a hydro-
phobic barrier that controls the access to the active site by only certain substrates and
remains mainly unchanged after ligand binding (44). Despite the similarities found in all
of the CHDL enzymes, important differences in (i) the arrangement and sequence of the
FIG 4 (A) Comparison of the OXA-type carbapenemases employed in this study, OXA-23 (gray), OXA-24 (yellow), OXA-51 (green), OXA-58
(pink), OXA-143 (blue), and OXA-235 (cyan), highlighting the side chain residues responsible of the major structural differences. The side
chain of the catalytic serine is also shown. (B) Detailed view of the -loop and neighbor turn involving 1-strand and 1-helix. Note the
relevant differences in the arrangement and sequence of the -loop among the enzymes studied. (C and D) Selected views of the
tunnel-like entrance to the active site of OXA-24 (C) and OXA-23 (D) enzymes. The position of the Tyr/Phe and Met residues that
are involved in this entrance are highlighted in green and red, respectively. The catalytic serine is shown in orange. Note how the
active site of OXA-24 containing a Try residue is more closed than the OXA-23 one having a Phe residue.
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-loop, which is located near the tunnel entrance, and (ii) the strength of the intra-
molecular interactions that constitute the tunnel-like structure were identified (Fig. 4A
and 5B). The differences in the -loop might cause significant variations in the plasticity
of these loops and therefore in the efficacy of the ligands. In addition, for OXA-24/40
and OXA-143 enzymes and with the exception of OXA-51-like, the presence of a Tyr
residue in the tunnel-like structure provides a more closed active site than OXA-23,
OXA-58, and OXA-235 (Fig. 4C and 5D), which might also be relevant for activity.
Docking studies carried out in the active site of the relevant carbapenemase, OXA-23
with LN-1-255, showed that the indolizine adduct obtained after covalent modification
of the catalytic Ser-79 by LN-1-255 would establish strong polar interactions with
residues Arg-259, Lys-216, Ser-126, and Thr-217 (Fig. S2). Specifically, the sulfinate
group would be anchored to the active site via an electrostatic interaction with the
guanidinium group of Arg-259 as well as hydrogen bonding with Thr-217. In addition,
the NH group would establish hydrogen bonding with the side chain of Ser-126. The
indolizine moiety would be embedded in the apolar pocket near the tunnel-like
entrance involving Val-128 and Leu-166. Remarkably, the large pocket close to the
active site would be partially occupied by the catechol moiety. The catechol moiety
would be quite flexible but would interact by hydrogen bonding with the -amino
group of Lys-216. The avibactam adduct would also establish strong polar interactions
with residues Arg-259, Lys-216, Ser-126, and Thr-217 (Fig. 5B). The contacts between
FIG 5 Selected view of inactivation of OXA-23 (A and B) and OXA-58 (C and D) from A. baumannii by LN-1-255 (A and C) and avibactam
(B and D) obtained by molecular docking studies. Hydrogen bonding and electrostatic interactions between the ligands and the enzymes
are shown as dashed blue lines. Relevant side chain residues are shown and labeled.
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the catechol moiety of LN-1-255 with the large pocket close to the active site would be
absent. Moreover, the predicted binding mode of the studied ligands, either Michaelis
complexes or ligand adducts, in the active site of OXA-58 (Fig. 5C and D), OXA-143, and
OXA-235 proved to be rather similar to that observed for OXA-23.
DISCUSSION
In the present study, we have described the inhibitory activity of a member of the
family of C2/C3 substitute penicillin sulfones and compared it to the inhibitory activities
of tazobactam and a new -lactamase inhibitor, avibactam, against the most clinically
relevant class D carbapenemases of A. baumannii. The CHDLs studied were selected
because they were the first isolated and constitute the main examples of each family
of CHDLs in A. baumannii (18).
These -lactamase inhibitors must penetrate the Gram-negative membrane to
effectively decrease the MICs of -lactam antimicrobials. The molecule LN-1-255, which
was previously described, coopts the microbial iron uptake system to traverse the outer
membrane, increasing the penetration rate (30, 31). LN-1-255 has previously proven
activity against OXA-1, OXA-10, and the CHDLs OXA-24/40 of A. baumannii and OXA-48
of Klebsiella pneumoniae (26, 33, 35). In the present study, we have demonstrated the
activity of LN-1-255 as a paninhibitor of all A. baumannii CHDLs. Our microbiological
data confirmed that LN-1-255 can penetrate the membrane at a high enough concen-
tration to be effective and thus was able to inhibit the main A. baumannii CDHLs. The
kinetic data presented here are in agreement with the microbiological data and, overall,
indicated that this compound inhibits the OXA carbapenemases with Ki values that
were significantly lower than those of avibactam and tazobactam. Susceptibility testing
showed that a combination treatment with imipenem–LN-1-255 or meropenem–LN-1-
255 significantly lowered the MICs against carbapenem-resistant A. baumannii strains
carrying CHLDs. The new compound did not show intrinsic antibiotic activity against
any of the clinical isolates and ATCC strains tested. However, a dose-dependent effect
was observed for this compound, as the observed MICs decreased more at a concen-
tration of 16 mg/liter than 4 mg/liter. Checkerboard assays indicated that a clinical
breakpoint of 2 mg/liter (susceptible) was reached at a concentration of 8 mg/liter of
LN-1-255, which is a reasonable concentration to reach in plasma during treatment with
other -lactamase inhibitors, such as avibactam or sulbactam (45, 46). The microbio-
logical and kinetics results described in the present study are in good agreement with
previous inhibition studies performed with these three inhibitors against class D
-lactamases OXA-24/40 (28, 32, 35) and with avibactam against OXA-23 (47).
Class D -lactamases have a broader profile of substrates in A. baumannii than other
classes of -lactamases. Some OXAs have limited substrate affinity and only hydrolyze
penicillins and first-generation cephalosporins (e.g., OXA-1), while others have ex-
tended their specificity to extended-spectrum cephalosporins (e.g., OXA-144, which is
an OXA-2-like enzyme) and carbapenems such as the OXAs included in this study and
OXA-48, which are the most clinically worrisome. The potent activity of LN-1-255
against all tested OXAs -lactamases is evident (32, 33, 35), and combinations of
antimicrobials such as ceftazidime or imipenem with this inhibitor could be good
options for treatment of CHDL-carrying A. baumannii.
Molecular docking studies were performed to ascertain if the binding mode of these
ligands in the serine active site of the enzymes could account for the observed
differences in inhibitory activity observed between the -lactamase inhibitors evalu-
ated in this study against CHDL enzymes. Comparison of the predicted binding mode
of the OXA–LN-1-255 and OXA–avibactam adducts obtained by molecular docking
revealed that both adducts would have similar polar (electrostatic and hydrogen-
bonding) interactions involving the groups that most contribute to anchoring the
ligands in the active site, the sulfate and sulfinate/carboxylate groups, with mostly the
same active-site residues, specifically, Arg-259, Thr-217, and Ser-126 (numbering for
OXA-23). However, significant differences were identified in the interactions of the
indolizine and catechol moieties with two nearby pockets, specifically (i) the tunnel-like
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entrance and (ii) the catalytic serine (Fig. 5). Those interactions involving residues
Val-128, Leu-166, and Lys-216 (numbering for OXA-23) would be absent from the
OXA-avibactam adducts, which might account for the higher efficiency of LN-1-255.
The search for new inhibitors against -lactamases is a key step in the fight against
bacterial resistance; however, while compounds that inhibit different classes of
-lactamases are being developed, few of them exhibit activity against the class D
enzymes. Avibactam is a non--lactam -lactamase inhibitor. It has good inhibitory
properties against clinically relevant enzymes, such as class A extended-spectrum
-lactamases (ESBL) and some carbapenemases, as well as class C -lactamases (47). It
can also inhibit certain class D -lactamases; however, while it is able to inhibit OXA-48
enzymes, it does not have good inhibition kinetics against OXA-24/40 (28). In the
present study, avibactam did not show any inhibitory activity against OXA-24/40 or any
of the other CHDLs tested, and the average measured k2/K for all enzymes was
approximately 170-fold lower for avibactam than that for LN-1-255. OXA-235 was
strongly inhibited by avibactam, which is in agreement with the microbiological data,
where avibactam mainly decreased the MICs to ampicillin.
Few other molecules are able to inhibit the class D -lactamases. Methylene penems
such as BRL 42715 and other new penem inhibitors have Kis in the nanomolar range
against OXA-1; however, against the carbapenemase OXA-24/40 they acted like sub-
strates, with no inhibition of this enzyme under mild conditions (26, 48–50). Methylene
penems, such as the penicillin sulfones (including LN-1-255), are derived from
-lactams, and some non--lactam derivatives (such as avibactam) are also being
developed against class D -lactamases, such as the phosphonates and boronic acids
(10). The phosphonates are also inhibitors with activity against OXA -lactamases and
have affinity in the nanomolar range against OXA-1 and OXA-10 (26, 51, 52). When they
were tested against OXA-24/40, the thiophenyl oxime-derived phosphonates had Ki
values in the micromolar range (53). Finally, a boronic acid (4,7-dichloro-1-benzothien-
2-yl-sufonyl-aminomethyl boronic acid) also had an IC50 against OXA-24/40 in the
micromolar range and thus is the first boronic acid-based class D -lactamase inhibitor
(54). Polycarboxylic acids could be a good scaffold for novel lipophilic inhibitors.
Designed through fragment-based lead discovery, these polycarboxylic acids showed
binding affinity against OXA-10 in the micromolar range. They are also promising
candidates in the search for a new group of class D -lactamase inhibitors (55–57).
Inhibition studies with the compound LN-1-255 also have been performed with
other classes of -lactamases. Activity was observed against class A -lactamases
(TEM-1, SHV-1, IMI-1, and others) and class C -lactamases (P99, MIR-1, and others) (30,
31, 58), thus showing a potent and broad-spectrum activity. However, no studies have
been published with 6-alkylidene-2-substituted penicillin sulfones against class B
-lactamases. The profound differences in enzyme mechanisms and active-site geom-
etry between serine- and metallo--lactamases greatly hamper the design of common
inhibitors for the four Ambler classes of -lactamases.
In summary, in the present study we describe the inhibitory activity of the com-
pound LN-1-255 against the class D carbapenemases of A. baumannii. Carbapenems in
combination with LN-1-255 were effective against these carbapenem-resistant A. bau-
mannii strains carrying -lactamases, and biochemical assays demonstrated that LN-1-
255 has better inhibitory efficiency than tazobactam or avibactam. Therefore, LN-1-255
represents a potential new therapeutic option in combination with carbapenems
against resistant A. baumannii strains. Additional preclinical studies in infectious animal
models are necessary to further develop this compound for clinical applications.
MATERIALS AND METHODS
Bacterial strains and media. The recipient strain for OXA enzymes was an antibiotic-susceptible A.
baumannii ATCC 17978 type strain, and blaOXA genes were isolated from previously studied clinical
strains of A. baumannii (12, 15, 16, 59, 60). The OXA-51-like gene used in this study was OXA-95, which
is the chromosomal blaOXA gene of the type strain ATCC 17978. Escherichia coli TG1 was used as the
recipient strain for cloning experiments, and E. coli BL21was used for expression experiments. All strains
used in this study are listed in Table 4.
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Bacterial strains were frozen in Luria-Bertani broth (LB) with 10% glycerol and were maintained
at 80°C until analysis. Strains of E. coli and A. baumannii were grown at 37°C in LB medium. When
necessary, LB medium was supplemented with ampicillin (20 mg/liter) or kanamycin (50 mg/liter)
(Sigma-Genosys Ltd., United Kingdom). MICs and checkerboard assays were performed in Mueller-Hinton
II broth (Becton, Dickinson and Company, Sparks, MD).
Susceptibility testing of antibiotics and inhibitors. When the blaOXA genes were codified in a
plasmid (blaOXA-23, blaOXA-58, and blaOXA-143), the plasmid DNA was purified using the GeneJET plasmid
miniprep kit (Thermo Fisher Scientific, MA) according to the manufacturer’s instructions. In the cases of
blaOXA-24/40, blaOXA-51-like, and blaOXA-235, which are chromosomal genes, genomic DNA was obtained
using the Wizard genomic DNA purification kit (Promega, Madison, WI). The blaOXA genes were amplified
using PrimeSTAR HS DNA polymerase (TaKaRa, Berkeley, CA) and a primer pair containing recognition
sites for the restriction enzyme XbaI (Fermentas, Glen Burnie, MD) (Table 5). The amplified DNA
fragments were purified with a GeneJET PCR purification kit (Thermo Fisher Scientific, Waltham, MA,
USA), digested with XbaI, and ligated into the pET-RA plasmid previously digested with XbaI (61) using
T4 DNA ligase (Thermo Fisher Scientific, Waltham, MA, USA). The expression of the enzymes was under
the control of the blaCTX-M-14 gene promoter previously cloned into the pET-RA plasmid, which also
carried a kanamycin resistance gene. These plasmid constructs (pET-RA-OXA-23, pET-RA-OXA-24/40,
pET-RA-OXA-51, pET-RA-OXA-58, pET-RA-OXA-143, and pET-RA-OXA-235) were used to transform E. coli
TG1 for subcloning and then transformed into the ATCC 17978 A. baumannii wild-type strain by selection
in LB plates containing 50 mg/liter of kanamycin.
MICs of ampicillin (Sigma-Genosys, Dorset, United Kingdom), imipenem (Actavis, Cork, Ireland), and
meropenem (Accordpharma, Middlesex, United Kingdom) were determined by broth microdilution, in
the presence and absence of inhibitors, according to CLSI criteria (62). The inhibitors used were
tazobactam (Sigma-Genosys, Dorset, United Kingdom), avibactam (Astrazeneca, London, United King-
dom), and LN-1-255, each at 4 and 16 mg/liter (Fig. 1). MICs of inhibitors were also determined. LN-1-255
TABLE 4 Laboratory strains and clinical isolates used in this work
Strain blaOXA genea Strain description
Reference
or source
E. coli BL21 NA F ompT hsdSB(rB mB) gal dcm ATCC
E. coli TG1 NA supE hsdΔ5 thi Δ(lac-proAB) F= [traD36 proAB lacIqΔM15] ATCC
A. baumannii Ab1 OXA-23 A. baumannii clinical isolate, isolated from bronchial
aspirate from Spain
60
A. baumannii RYC 52763/97 OXA-24/40 A. baumannii clinical isolate, isolated from bronchial
aspirate from Spain, first description of OXA-24/40
12
A. baumannii ATCC17978 OXA-95 (OXA-51-like) A. baumannii type strain, OXA-51 like variant OXA-95,
completely sequenced reference strain
ATCC
A. baumannii HRS1 OXA-58 A. baumannii clinical isolate from Spain 59
A. baumannii 135040 OXA-143 A. baumannii clinical isolate, isolated from blood culture
from Brazil, first description of OXA-143
15
A. baumannii AF 401 OXA-235 A. baumannii clinical isolate, isolated from small intestine
from Mexico, first description of OXA-235
16
aNA, not available.
TABLE 5 Primers used in this work
blaOXA gene
Primer sequencea
Amplification and sequencing of blaOXA genes Amplification and purification of OXA enzymes
OXA-23 OXA-23fw, GCTCTAGAGCATGAATAAATATTTTACTTGCT OXA-23fw, CGCGGATCCTTAATAAATGAAACCCCGAGTC
OXA-23rv, GCTCTAGAGCTCAGATTATAAAAGGCCCAT OXA-23rv, CCGGAATTCTTAAATAATATTCAGCTGTTTTAATG
OXA-24 OXA-24fw, GCTCTAGAGCATGAAAAAATTTATACTTCC OXA-24fw, AAGGATCCTCTATTAAAACTAAATCTGAAG
OXA-24rv, GCTCTAGAGCTTAAATGATTCCAAGATTTT OXA-24rv, AAAGAATTCTTAAATGATTCCAAGATTTTC
OXA-95 (OXA-51-like) OXA-51fw, GCTCTAGAGCATGAACATTAAAGCACTCTT OXA-51fw, CGCGGATCCAATCCAAATCACAGCGCTTCAAA
OXA-51rv, GCTCTAGAGCCTATAAAATACCTAATTGTT OXA-51rv, CCGGAATTCCTATAAAATACCTAATTGTTCTAAA
OXA-58 OXA-58fw, GCTCTAGAGCATGAAATTATTAAAAATATT OXA-58fw, CGCGGATCCGAGCATAGTATGAGTCGAGCA
OXA-58rv, GCTCTAGAGCTTATAAATAATGAAAAACAC OXA-58rv, CCGGAATTCTTATAAATAATGAAAAACACCCAAC
OXA-143 OXA-143fw, GCTCTAGAGCATGAAAAAATTTATACTTCC OXA-143fw, CGCGGATCCTGCTCATCTATTCAAACTAAATTT
OXA-143rv, GCTCTAGAGCTTATATAATCCCTAAATTCT OXA143rv, TCCCCCGGGTTATATAATCCCTAAATTCTCTAAT
OXA-235 OXA-235fw, GCTCTAGAGCATGAAAACTCTTATTTTGTTGC OXA-235fw, CCGGAATTCTTGCCTGTTTCAAATTCGTCC
OXA-235rv, GCTCTAGAGCTTACCCTTCAGCTTTCGGAT OXA-235rv, CCGCTCGAGTTACCCTTCAGCTTTCGGATA
aThe underlined sequences represent sites for restriction enzymes.
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was prepared at the Center for Research in Biological Chemistry and Molecular Materials (CIQUS,
University of Santiago of Compostela, Spain), as described previously (58). Turbidity was recorded in
96-well plates after 20 to 22 h of incubation at 37°C in Mueller-Hinton II broth. The MICs presented here
are the means from three independent replicates.
The activity of inhibitors in combination with imipenem was also assessed in checkerboard assays
(63). After 20 h of incubation, 10 l of alamarBlue reagent (Thermo-Scientific, Waltham, MA, USA) was
added to all wells and incubated for 4 h at 37°C to identify those wells containing viable bacteria.
Purification of OXA carbapenemases. To purify the CHDL enzymes, the blaOXA genes were
amplified and DNA fragments were cloned into the pGEX-6P-1 vector using BamHI and EcoRI sites,
except in the cases of blaOXA-143 and blaOXA-235, where BamHI/XmaI and BamHI/XhoI restriction sites,
respectively, were used. This genetic construction led to a fusion protein containing glutathione
S-transferase (GST) and the target enzymes. The signal peptide of the CHDLs was not included in the
fusion proteins. Cloning procedures were similar to those described above, using the primers described
in Table 5. The genetic constructs were introduced into E. coli BL21 by electroporation and selection in
LB plates containing 50 mg/liter of ampicillin. The recombinant -lactamases were then purified to
homogeneity using the GST gene fusion system (Amersham Pharmacia Biotech, Munich, Germany)
according to the manufacturer’s instructions. After SDS-PAGE, the purified proteins appeared as a band
of approximately 29 kDa (95% purity). Spots with proteins were excised from gels, washed, digested
with trypsin, and identified by matrix-assisted laser desorption ionization-tandem time of flight using the
software ProteinPilot4.0.
Kinetic parameters. All experiments were performed in triplicate at 25°C in 50 mM sodium
phosphate (pH 7.0) with 20 mM sodium bicarbonate (64), in 1.0-cm-path-length cuvettes, using purified
proteins under steady-state conditions on an Epoch 2 microplate spectrophotometer (Biotek, VT, USA) as
previously described (33).
Measurements of hydrolysis were performed with nitrocefin (NCF) (Oxoid, Hampshire, United King-
dom) at a wavelength of 482 nm (extinction coefficient, 15,900 M1 cm1). The apparent kcat, Vmax, and
Km were determined by measuring the initial reaction velocities at different nitrocefin concentrations.
The data were fit to the Michaelis-Menten equation (nonlinear least-square fit) (equation 1) (65).
v  Vmax 	 S ⁄ Km 
 S (1)
For inhibition kinetics, the IC50 was calculated as the inhibitor concentration resulting in 50%
reduction of nitrocefin hydrolysis after 10 min of preincubation of the enzyme and inhibitor at 25°C, as
previously described (35).
The apparent Ki was obtained as a competitive inhibition constant (Ki app) in the presence of
nitrocefin as previously described (66). Increasing concentrations of each inhibitor were added to the
enzyme and nitrocefin mixtures, and the initial velocities (vi) were measured. The nitrocefin concentra-
tions used were 350 M for OXA-23 and OXA-51, 150 M for OXA-143 and OXA-235, and 100 M for
OXA-24/40 and OXA-58 (2- to 3-fold over the Km) (Table 2). Inverse initial velocities (1/v0) were plotted
against inhibitor concentrations ([I]), and the data were fit to a linear equation where the y intercept
divided by the slope of the line was defined as the Ki app observed. The initial velocity (v0) was determined
by equation 2. Ki app observed then was corrected for nitrocefin affinity using equation 3.
v0  Vmax 	 S ⁄ Km NCF 	 1 
 l ⁄ Ki app 
 S (2)
Ki appcorrected  Ki appobserved ⁄ 1 
 S ⁄ Km NCF (3)
The inhibitor complex inactivation rate (kinact) in the presence of nitrocefin was measured and the KI
determined as previously described (65, 67). Nitrocefin was used as a reporter substrate with the same
concentration described above and increasing concentrations of inhibitors over a 15-min time course (45
min for OXA-51-like enzyme). The kobs values were determined using nonlinear least-squares fit of the
data, employing GraphPad software (La Jolla, CA, USA) and equation 4.
A  A0 
 vf 	 x 
 v0  vf 	 1  expkobs 	 x ⁄ kobs (4)
Here, A is absorbance, v0 is initial velocity, vf is the final velocity, and x is time. The kobs values were
plotted against inhibitor concentrations to determine kinact and KI using equation 5. The KI value was
corrected using equation 3.
kobs  kinact 	 l ⁄ Kl 
 l (5)
The apparent onset of acylation (k2/K) was determined as the slope of the line obtained by plotting
[I] against kobs (33). This value was corrected for nitrocefin affinity by following equation 6.
k2 ⁄ K  k2 ⁄ kobstimesS ⁄ Km NCF 
 1 (6)
The turnover numbers (tn), defined as the inhibitor/enzyme ratio (I:E) necessary for 90% inhibition
of nitrocefin hydrolysis, were determined after 20 h of incubation with increasing concentrations of
inhibitors and 10 nM enzymes, with various molar I:E ratios (35). Incubations were performed in a final
reaction volume of 200 l, and nitrocefin was added immediately before measuring in order to
determine the residual enzyme activity for 180 s.
Binding studies using molecular docking. The binding mode of LN-1-255 and avibactam in the
active site of the major representative enzymes of all families of CHDLs described to date in A. baumannii
were analyzed by docking studies by using the available crystal structures. As no three-dimensional
structures are available for OXA-143 and OXA-235, their corresponding homology models were con-
structed as indicated below.
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Building of the wild-type OXA-143 and OXA-235 models. The SWISS-Model homology modeling
web server was used to model the three-dimensional structures of OXA-143 and OXA-235 (40). The
coordinates of the crystallographically determined OXA-24/40 (2.25 Å; PDB code 3PAG) (44) and OXA-51
(2.0 Å; PDB code 4ZDX) (22) were chosen as the main templates for building the two models.
Docking studies. The docking studies were carried out using GOLD 5.2 (http://www.ccdc.cam.ac
.uk/solutions/csd-discovery/components/gold/), and the enzyme geometries of OXA-23 (2.14 Å; PDB
code 4JF4) (38) and OXA-58 (2.6 Å; PDB code 4Y0U) (39) and the homology models of OXA-143 and
OXA-235 were created. The crystal structures of PDB codes 4JF4 and 4Y0U were chosen because the
position of the modified ligand is defined. Ligand geometries were minimized using AM1 Hamiltonian as
implemented in the program Gaussian 09 (68) and used as MOL2 files. Each ligand was docked in 25
independent genetic algorithm (GA) runs, and for each of these a maximum number of 100,000 GA
operations were performed on a single population of 50 individuals. Operator weights for crossover,
mutation, and migration in the entry box were used as default parameters (95, 95, and 10, respectively),
as well as the hydrogen bonding (4.0 Å) and van der Waals (2.5 Å) parameters. For OXA-23 and OXA-58,
the position of the adducts present in the above-mentioned crystal structures were used to define the
active site, whereas for the homology models, the position of the catalytic serine was employed. For all
cases, the radius was set to 10 Å. The “flip ring corners” flag was switched on, while all other flags were
off. The GOLD scoring function was used to rank the ligands in order of fitness. Figures depicting
structures were prepared using PYMOL (69).
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